Axsome Therapeutics (NASDAQ:AXSM) Price Target Raised to $195.00 at Mizuho

Axsome Therapeutics (NASDAQ:AXSM) had its price objective raised by equities research analysts at Mizuho from $137.00 to $195.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The firm currently has an “outperform” rating on the stock. Mizuho’s price target indicates a potential upside of 53.45% from the company’s previous close.

Several other research analysts have also weighed in on AXSM. Truist Financial boosted their price target on Axsome Therapeutics from $180.00 to $190.00 and gave the stock a “buy” rating in a research report on Monday, February 3rd. Leerink Partners boosted their target price on shares of Axsome Therapeutics from $110.00 to $150.00 and gave the stock an “outperform” rating in a report on Monday. Needham & Company LLC reiterated a “buy” rating and issued a $133.00 price target on shares of Axsome Therapeutics in a research note on Monday. Robert W. Baird boosted their price objective on shares of Axsome Therapeutics from $112.00 to $116.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 13th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $139.00 target price on shares of Axsome Therapeutics in a research note on Wednesday, January 29th. One analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Axsome Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $141.73.

Axsome Therapeutics Trading Up 20.2 %

Shares of NASDAQ:AXSM opened at $127.08 on Tuesday. The company’s 50-day moving average price is $94.72 and its two-hundred day moving average price is $91.78. Axsome Therapeutics has a one year low of $64.11 and a one year high of $132.25. The company has a debt-to-equity ratio of 1.97, a current ratio of 2.44 and a quick ratio of 2.37. The stock has a market capitalization of $6.16 billion, a PE ratio of -19.46 and a beta of 1.05.

Axsome Therapeutics (NASDAQ:AXSM) last released its earnings results on Tuesday, November 12th. The company reported ($1.34) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.38) by $0.04. Axsome Therapeutics had a negative return on equity of 158.36% and a negative net margin of 91.87%. The business had revenue of $104.76 million for the quarter, compared to the consensus estimate of $98.71 million. During the same quarter in the previous year, the business earned ($1.32) earnings per share. On average, equities analysts forecast that Axsome Therapeutics will post -4.7 EPS for the current fiscal year.

Hedge Funds Weigh In On Axsome Therapeutics

A number of large investors have recently made changes to their positions in AXSM. Xponance Inc. grew its stake in shares of Axsome Therapeutics by 11.6% in the fourth quarter. Xponance Inc. now owns 2,659 shares of the company’s stock valued at $225,000 after acquiring an additional 277 shares in the last quarter. Intech Investment Management LLC boosted its holdings in Axsome Therapeutics by 46.5% in the 4th quarter. Intech Investment Management LLC now owns 16,028 shares of the company’s stock valued at $1,356,000 after purchasing an additional 5,087 shares during the period. Cibc World Markets Corp acquired a new position in shares of Axsome Therapeutics during the 4th quarter worth approximately $291,000. Corient Private Wealth LLC bought a new position in shares of Axsome Therapeutics during the fourth quarter worth approximately $239,000. Finally, Royce & Associates LP raised its position in shares of Axsome Therapeutics by 64.4% in the fourth quarter. Royce & Associates LP now owns 37,000 shares of the company’s stock valued at $3,131,000 after buying an additional 14,500 shares in the last quarter. Institutional investors own 81.49% of the company’s stock.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.